Virax Biolabs Presentation from the 19th World Immune Regulation Meeting: “Evaluation of T cell dysfunction in Post Acute Infection Syndromes”

Dr. Nigel McCracken, our Chief Operating Officer, will present on “Evaluation of T cell dysfunction in Post Acute Infection Syndromes” at the 19th World Immune Regulation Meeting (WIRM) in Davos, Switzerland today (March 12th) at 8pm in Foyer A1. For those not able to join us in Davos, you can have a look at the poster here or use the link below to download a copy for a closer look:

Dr. Ailsa Snaith Joins the Virax Biolabs Team

We’re excited to welcome Dr. Ailsa Snaith to the Virax Biolabs team today – she will be the newest member of our Advisory Board. A scientist and clinician with a deep résumé in both academic and non-academic settings, Dr. Snaith will bring years of powerful experience to help us augment our ViraxImmune™ platform. With her recent focus in the role of pathogens in chronic illness and neurodegeneration, she shares our deep passion for our research aims. Read more about her here by visiting her bio.

Jeff Hurwitz and Gordon Powell Join the Virax Biolabs Team

This week, we’re pleased to be welcoming Jeff Hurwitz and Gordon Powell to the team. Their decades of experience in the in-vitro diagnostics (IVD) space will be a great addition to our growing team and will aid us as we expand into new markets. Jeff (Business Development, Americas) will be an agile lead for our market entry in the United States and beyond. For over 25 years, he has spearheaded US sales and commercial strategies for startups and large, global teams alike. Gordon (Advisory Board Member) will utilize his over 30 years of life science expertise to help us take our marketing and commercial strategy to the next level. He is excited to leverage his proven specialization in point-of-care IVDs to augment our business offerings.